Low-density lipoprotein and apolipoprotein B: Clinical use in patients with coronary heart disease

被引：12

作者：

Cromwell W.C. ^{[1
]}

Barringer T.A. ^{[1
]}

机构：

[1] Division of Atherosclerosis and Lipoprotein Disorders, Presbyterian Cardiovascular Institute, Charlotte, NC 28204

来源：

Current Cardiology Reports | 2009年 / 11卷 / 6期

关键词：

Arterioscler Thromb Vasc Biol; Coronary Heart Disease Event; Framingham Offspring Study; LDLC Level; Quebec Cardiovascular Study;

D O I：

10.1007/s11886-009-0067-z

中图分类号：

学科分类号：

摘要：

Managing low-density lipoprotein (LDL) is an integral part of clinical practice. What remains controversial is whether we are using the best measure of LDL quantity for this purpose. Historically, the cholesterol content of LDL particles (LDLC) has been used to express LDL quantity. However, because of variability in the cholesterol carried in LDL particles, frequent disagreement occurs between LDLC and particle measures of LDL quantity, including apolipoprotein B-100 (apo B) or nuclear magnetic resonance (NMR) LDL particle number (LDL-P). Studies consistently demonstrate apo B and LDL-P are superior predictors of coronary heart disease (CHD) risk and superior indicators of low CHD risk on lipid-lowering therapy. Recent recommendations advocate that, in addition to LDLC and non-high-density lipoprotein cholesterol, apo B (or NMR LDL-P) be used as a target of therapy. This article reviews the rationale supporting these recommendations and provides a model for integrating LDL particle measures in clinical practice. © 2009 Springer Science+Business Media, LLC.

引用

页码：468 / 475

页数：7

共 48 条

[1]

Nielsen L.B., Transfer of low density lipoprotein into the arterial wall and risk of atherosclerosis, Atherosclerosis, 123, 1-2, pp. 1-15, (1996)

[2]

Tabas I., Williams K.J., Boren J., Subendothelial lipoprotein retention as the initiating process in atherosclerosis: Update and therapeutic implications, Circulation, 116, 16, pp. 1832-1844, (2007)

[3]

Third Report of the National Cholesterol Education Program (NCEP), 106, pp. 3143-3421, (2002)

[4]

Grundy S.M., Cleeman J.I., Bairey Merz C.N., Brewer Jr. H.B., Clark L.T., Hunninghake D.B., Pasternak R.C., Smith Jr. S.C., Stone N.J., Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines, Circulation, 110, 2, pp. 227-239, (2004)

[5]

Hayward R.A., Hofer T.P., Vijan S., Narrative review: Lack of evidence for recommended low-density lipoprotein treatment targets: A solvable problem, Ann Intern Med, 145, pp. 520-530, (2006)

[6]

Sniderman A.D., Furberg C.D., Keech A., Roeters Van Lennep J.E., Frohlich J., Jungner I., Walldius G., Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment, Lancet, 361, 9359, pp. 777-780, (2003)

[7]

Barter P.J., Ballantyne C.M., Carmena R., Et al., Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: Report of the thirty-person/ten-country panel, J Intern Med, 259, pp. 247-258, (2006)

[8]

Gotto Jr A.M., Whitney E., Stein E.A., Et al., Relation between baseline and on-treatment Lipid parameters and first acute major coronary events in the air force/texas coronary atherosclerosis prevention study (AFCAPS/TexCAPS), Circulation, 101, pp. 477-484, (2000)

[9]

Simes R.J., Marschner I.C., Hunt D., Colquhoun D., Sullivan D., Stewart R.A.H., Hague W., Keech A., Thompson P., White H., Shaw J., Tonkin A., Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) trial: To what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?, Circulation, 105, 10, pp. 1162-1169, (2002)

[10]

Van Lennep J.E., Westerveld H.T., Van Lennep H.W., Et al., Apolipoprotein concentrations during treatment and recurrent coronary artery disease events, Arterioscler Thromb Vasc Biol, 20, pp. 2408-2413, (2000)

← 1 2 3 4 5 →